Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

quantum physics

- PMLiVE

Recursion raises $121m for AI-led drug discovery

Funds will fuel in house pipeline and tech

- PMLiVE

Merck says it has plenty in the pipe beyond Keytruda

It has the firepower, but is Merck seeking a big deal?

- PMLiVE

Merck & Co adds to immunotherapy again with $773m Tilos buy

Specialises in TGFβ complex-targeting therapies

- PMLiVE

Sanofi taps Google’s expertise for digital transformation

Pharma giant embraces AI with new partnership

- PMLiVE

AZ reports stellar results for Lynparza in pancreatic cancer

Plans to file as soon as possible

- PMLiVE

Merck bulks up in cancer with $2.2bn Peloton buy

Another significant bolt-on in oncology

- PMLiVE

Myovant’s fibroids drug clears phase 3 trial, but shares sink

Investors concerned on how it stacks up against AbbVie rival

- PMLiVE

Data regulations impeding AI use in drug research

Lack of data specialists another concern

Artificial Intelligence: a new character in the storytelling of drug development and discovery?

Written by Edward Jones, Junior Medical Writer. Bedrock is dedicated to creating valuable and powerful stories to engage audiences that drive an improvement in the provision of health. This focus...

Bedrock Healthcare Communications

- PMLiVE

New biotech accelerator launched in Cambridge, UK

Start Codon aims to invest in 50 start-up companies over the next five years

- PMLiVE

Second chance for AstraZeneca’s selumetinib with breakthrough designation

Part of R&D and commercial collaboration with MSD

- PMLiVE

Celgene and Exscientia sign AI drug discovery deal in oncology and autoimmunity

Firm says it cuts discovery timelines by 75%

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links